$MNKD

Binder Steven B. sold $213K of MNKD

Binder Steven B. sold 52,485 shares of MANNKIND CORP (MNKD) at $4.06 ($0.21M total) on 2026-07-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Binder Steven B.
Published Jul 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MNKD
Neutral
medium confidence
Mentioned
$MNKD
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

Traders may monitor insider activity for sentiment, but this specific disclosure lacks any new company fundamentals, guidance, or regulatory/clinical catalysts.

02

Market read

A routine director sale is disclosed; absent other catalysts, it is unlikely to drive a durable repricing.

03

What to watch

The article does not state whether other insiders sold/bought, nor does it provide context on total insider holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-17, after-hours/late session disclosure window

Background

The article is an SEC Form 4 insider transaction disclosure for MannKind Corp, reported as an open-market sale by a director under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$MNKDNeutralMedium confidence
Context

MannKind director Steven B. Binder sold 52,485 shares in an open-market transaction for about $213,089 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other news.

Evidence & confidence

The filing is a routine Form 4 open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes in the text.

Market effects

No sector read-through is provided; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • MannKind Corp

    US-listed company (MNKD) whose director insider sale is disclosed on Form 4.

  • Steven B. Binder

    Director who sold 52,485 shares at $4.0600/share on 2026-07-17 under a 10b5-1 plan.

Related articles

$MNKDMedAI 8/10

MANNKIND CORP (MNKD): Results of Operations and Financial Condition

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mnkd-ex99_1.htm EX-99.1 EX-99.1 MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza ® following FDA approval o FUROSCIX ReadyFlow™ aut

$MNKDMed

MannKind's Nintedanib DPI Shows Favorable Safety In IPF Patients

MannKind (MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation in idiopathic pulmonary fibrosis. In a randomized, double-blind, placebo-controlled trial of 27 patients, it met the primary objective of safety and tolerability, with no serious adverse events, GI effects, bronchospasm, or discontinuations. MannKind is enrolling Phase 2 INFLO-2.

$MNKDMedAI 8/10

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MannKind (Nasdaq: MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation (DPI) in idiopathic pulmonary fibrosis. In 27 patients, it met safety and tolerability goals with no serious adverse events, no bronchospasm or diarrhea, and no discontinuations. Phase 2 INFLO-2 is enrolling about 210 patients.

$MNKDMedAI 8/10

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - MannKind (NASDAQ:M

The FDA approved MannKind’s Furoscix ReadyFlow, a furosemide injection autoinjector for edema in adults with heart failure or chronic kidney disease. MannKind said it delivers an 80 mg/mL dose in under 10 seconds. The company also announced a private placement of about $50 million to fund general purposes, including a $45 million contingent value rights payment. MNKD shares rose to about $4.16.